Hero image

COVID-19

The COVID-19 pandemic is an unrivaled scientific and global health challenge. As one of the very few companies that has continued to invest in both vaccines and anti-infective medicines, we have a special responsibility to help.

We're rising to the challenge

We’ve been committed to trying to develop an effective response to the COVID-19 pandemic since it was first recognized. We know that success will require global collaboration among countries and companies and more.

Our work may feel like a marathon at the speed of a sprint, but our scientific efforts in addressing COVID-19 won’t stop.

Putting patients first

We believe that no one should go without the medicines or vaccines they need. That's why we are taking a number of new steps to support patients.

We're taking a number of new steps to help support patients in the U.S. who may have lost their jobs and insurance coverage and we will continue to ensure access to Merck medicines at no cost for eligible U.S. patients through our Merck Patient Assistance Program.

To learn more about resources Merck has available for patients who need help during the COVID-19 pandemic and beyond, call 1-800-672-6372 or visit our information page.

Pursuing multiple pathways 

Success requires collaboration. In a collaboration with Ridgeback Bio, we are researching a novel antiviral candidate. In addition, we are researching two SARS-CoV-2/COVID-19 vaccine development efforts – one through a collaboration with IAVI and the other through our acquisition of Themis.

We believe a range of medicines and vaccines will be needed to end the pandemic, and we will continue to pursue multiple pathways, including an expansive internal research program, and collaborate with others.

See our previous announcements:

Stepping up as an industry

As has been the case with many diseases, we are optimistic that our industry’s efforts will create new tools to address the pandemic and that the unprecedented collaboration we are seeing today will accelerate these efforts.

We partnered with our fellow biopharmaceutical companies to sign a historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines.

Giving back

In response to the pandemic, we changed our volunteer policy to support employees with nursing and other medical backgrounds. 

Recognizing the need for additional health care professionals, including doctors, nurses and medical laboratory technicians, to assist in regions where COVID-19 is spreading, on March 21 we deployed a new program to enable our medically trained employees to volunteer their time to aid their communities while maintaining their base pay.

Learn more about philanthropy at Merck

Stories that inspire our work

Our work in the fight against COVID-19 reaches across all corners of our company, our personal lives and our communities, where many of our medically trained employees have volunteered their time.